• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry

20 de February de 2026
Hemasphere. 2026 Feb 18;10(2):e70301. doi: 10.1002/hem3.70301.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-02-20 11:00:002026-02-20 11:00:00A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry

Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence

19 de February de 2026
Cell Death Discov. 2026 Feb 19. doi: 10.1038/s41420-026-02967-6.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-02-19 11:00:002026-02-19 11:00:00Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence

Early diagnosis of fetal ganglionic eminence cysts: imaging, outcome and genetic associations, revealing role of mitochondrial dysfunction

12 de February de 2026
Ultrasound Obstet Gynecol. 2026 Feb 12. doi: 10.1002/uog.70180.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-02-12 11:00:002026-02-12 11:00:00Early diagnosis of fetal ganglionic eminence cysts: imaging, outcome and genetic associations, revealing role of mitochondrial dysfunction

Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma

7 de February de 2026
Eur J Haematol. 2026 Feb 6. doi: 10.1111/ejh.70126. Online ahead…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-02-07 11:00:002026-02-07 11:00:00Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma

Charting the evolving landscape of kinase hinge-binding chemotypes beyond flatland: a systematic analysis and opportunities for sp3-rich binders

31 de January de 2026
Eur J Med Chem. 2026 Jan 19;306:118595. doi: 10.1016/j.ejmech.2026.118595.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-31 11:00:002026-01-31 11:00:00Charting the evolving landscape of kinase hinge-binding chemotypes beyond flatland: a systematic analysis and opportunities for sp3-rich binders

Glucose deprivation drives LIF-dependent lung cancer

30 de January de 2026
Nat Metab. 2026 Jan 30. doi: 10.1038/s42255-025-01437-0. Online…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-30 11:00:002026-01-30 11:00:00Glucose deprivation drives LIF-dependent lung cancer

Immune biomarkers of increased infection risk in multiple myeloma

29 de January de 2026
Blood. 2026 Jan 29:blood.2025031744. doi: 10.1182/blood.2025031744.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-29 11:00:002026-01-29 11:00:00Immune biomarkers of increased infection risk in multiple myeloma

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study

22 de January de 2026
EClinicalMedicine. 2026 Jan 9;91:103753. doi: 10.1016/j.eclinm.2025.103753.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-22 11:00:002026-01-22 11:00:00HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study

It’s time to reimagine reimbursement for CAR T-cell therapy

21 de January de 2026
Am J Manag Care. 2025 Dec;31(Spec. No. 13):SP922-SP929. doi:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-21 11:00:002026-01-21 11:00:00It’s time to reimagine reimbursement for CAR T-cell therapy

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study

13 de January de 2026
Blood Adv. 2026 Jan 13:bloodadvances.2025018152. doi: 10.1182/bloodadvances.2025018152.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-13 11:00:002026-01-13 11:00:00Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma

7 de January de 2026
Blood Adv. 2026 Jan 7:bloodadvances.2025018546. doi: 10.1182/bloodadvances.2025018546.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-07 11:00:002026-01-07 11:00:00Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma

Promiscuously bioactive compounds are prevalent in widely used commercial drug repurposing libraries

6 de January de 2026
Eur J Med Chem. 2025 Dec 31;305:118550. doi: 10.1016/j.ejmech.2025.118550.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-06 11:00:002026-01-06 11:00:00Promiscuously bioactive compounds are prevalent in widely used commercial drug repurposing libraries
Page 6 of 87«‹45678›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}